This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Interleukin Genetics Reports Fourth Quarter And Year End 2012 Financial Results

Fourth Quarter Results

Revenue for the quarter ended December 31, 2012 was $0.3 million, compared to $0.6 million for the same period in 2011. The decrease is primarily attributable to decreased genetic testing revenue as a result of sales through the Amway Global sales channel.

Research and development expenses were $0.3 million for the quarter ended December 31, 2012, compared to $0.4 million for the quarter ended December 31, 2011. The decrease is primarily attributable to decreased consulting costs partially offset by increased compensation expenses as compared to the year ended December 31, 2011.

Selling, general and administrative expenses were $0.8 million for the quarter ended December 31, 2012, compared to $1.1 million for the same period in 2011. The decrease is primarily attributable to decreases in sales commissions paid to Amway Global as part of our Merchant Channel and Partner Store Agreement, compensation expenses and depreciation.

The Company reported a loss from continuing operations of $1.2 million, or $(0.03) per basic and diluted common share, for the fourth quarter of 2012, compared to $1.4 million or $(0.04) per basic and diluted common share for the same period in 2011.

As of December 31, 2012, the Company had cash and cash equivalents of $1.2 million, compared to $1.7 million of cash and cash equivalents on December 31, 2011. As of December 31, 2012, the Company had drawn the full $14.3 million under credit facilities with Pyxis Innovations Inc., an affiliate of Alticor. This facility currently becomes due on March 31, 2014.

The Company expects that its current and anticipated financial resources, including the $1.3 million available as of December 31, 2011 under the credit facility with Pyxis, are adequate to maintain current and planned operations only through April 30, 2013 and continues to work on sources of funding. The Company’s independent registered public accounting firm has included an explanatory paragraph in their opinion in connection with the 2012 audit, relating to the Company's ability to continue as a going concern.

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.66 -0.09%
FB $118.58 0.85%
GOOG $698.30 0.76%
TSLA $241.82 0.44%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs